Direct oral anticoagulants (DOACs) are the standard treatment for atrial fibrillation (AF), but a recent study in JACC Advances suggests cost concerns may lead doctors to reconsider warfarin for low-risk patients. The research examined 58,634 AF patients—half using DOACs, half using warfarin—and determined that while DOACs generally outperform warfarin, their advantage for low-risk individuals is negligible. The absolute risk reduction for this group was only 0.3% per year, indicating warfarin could serve as a reasonable alternative when DOACs are financially out of reach.
The study identified six key factors that increase the risk of adverse outcomes, such as stroke, bleeding, or death, when patients take warfarin instead of a DOAC. These include older age (hazard ratio: 1.55), male sex (hazard ratio: 1.30), impaired kidney function (hazard ratio: 2.21), lower body mass index (hazard ratio: 1.25), first-time use of a vitamin K antagonist (hazard ratio: 1.17), and nonparoxysmal AF (hazard ratio: 1.31).
Patients were categorized into three risk groups using the TIMI-AF score. Low-risk individuals faced an annual adverse-outcome rate of 3.5%, compared to 7.6% for intermediate-risk and 12.9% for high-risk patients. The lead author, Robert P. Giugliano, MD, stressed that these findings apply most directly to low-risk patients, where DOACs offer minimal benefit over warfarin.
Warfarin’s hidden costs outweigh convenience for some
For patients unable to afford DOACs, often due to high copays, warfarin may be the only practical choice, particularly if their risk profile is low. Georgios Syros, MD, a cardiac electrophysiologist, noted that some patients face hundreds of dollars in out-of-pocket costs for DOACs, making warfarin more accessible for those with minimal risk factors. However, warfarin requires frequent blood monitoring to maintain therapeutic levels, and adherence in real-world settings is often poor. The study found that only 65% of warfarin patients stayed within the target range, a figure likely even lower in clinical practice. This inconsistency raises concerns about effectiveness, especially for higher-risk patients who could suffer the most from switching.
Read Also: Tirzepatide and semaglutide have similar asthma risks
Despite these challenges, DOACs remain the preferred treatment for most AF patients when accessible. They eliminate the need for dietary restrictions, lab tests, and complex drug interactions associated with warfarin. Rajesh Kabra, MD, a cardiology specialist, described DOACs as “more convenient” for both patients and doctors, though he acknowledged that TIMI-AF scores, used in this study, are rarely applied in everyday practice.
Instead, clinicians typically rely on CHA₂DS₂-VASc and HAS-BLED scores to guide treatment decisions. Kabra stated he would still recommend DOACs for patients who can afford them, regardless of risk level, while reserving warfarin for those unable to access newer medications. This approach reflects a broader consensus: DOACs are superior when available, but cost remains a major obstacle for many.
Insurance gaps leave high-risk patients at higher peril
The research highlights a conflict between medical best practices and financial constraints. For low-risk patients, warfarin may be sufficient, but for those at higher risk, limited access to DOACs could lead to worse outcomes. Giugliano pointed out that older patients, who often benefit most from DOACs, are the least likely to have insurance coverage, leaving them vulnerable to poorer results with warfarin. The study also reveals that anticoagulation treatment extends beyond clinical decisions, shaped instead by insurance policies, out-of-pocket costs, and the challenges patients face in working through the healthcare system. While warfarin can serve as a temporary solution for low-risk individuals, the ideal approach would ensure DOACs are accessible to all who need them.